Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma.

ABSTRACT:

Background & aims

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Although hepatectomy and transplantation have significantly improved survival, there is no effective chemotherapeutic treatment for HCC and its prognosis remains poor. Sustained activation of telomerase is essential for the growth and progression of HCC, suggesting that telomerase is a rational target for HCC therapy. Therefore, we developed a thymidine analogue pro-drug, acycloguanosyl-5'-thymidyltriphosphate (ACV-TP-T), which is specifically activated by telomerase in HCC cells and investigated its anti-tumour efficacy.

Methods

First, we verified in vitro whether ACV-TP-T was a telomerase substrate. Second, we evaluated proliferation and apoptosis in murine (Hepa1-6) and huma

SUBMITTER: Tarocchi M 

PROVIDER: S-EPMC4309885 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature